Successful ATMP-Symposium 2025
Successful ATMP-Symposium 2025 – Save the Date for 2026: 02 December. Last November more than 130 participants gained fascinating insights into up-to-date research, technological and regulatory developments by researchers, entrepreneurs and regulators: The Product is the Process – Is it? Manufacturing and Translation of ATMP and Tissue-& Cell-based products. Save the Date for 2026: 02 December, Potsdam, Germany
In regenerative medicine, cell or gene therapy: driven by remarkable research and clinical success, innovative therapy and product concepts for advanced therapy medicinal products (ATMPs) are in the focus of interest. A complex and dynamic regulatory environment has emerged which needs expert exchange.
Organized by bbb biotechnologieverbund berlin-brandenburg e.V., Paul-Ehrlich-Institut, German ZLG (Central Office of the Federal States for Health Protection), German Stem Cell Network GSCN, HealthCapital Berlin Brandenburg and Berlin Partner für Wirtschaft und Technologie GmbH.
, , :
Dr. Ralf Sanzenbacher, Paul-Ehrlich-Institut, Langen, Germany
„Welcome address“
Prof. Dr. Heiko Lickert, Helmholtz Munich and Technische Universität München, Germany
„Beta cell replacement therapies for Diabetes: Where do we stand?“
Prof. Dr. Prof. Dr. Caspar Franzen, Krystal Biotech, Inc., Pittsburgh, USA
„Beremagene geperpavec: First approved topical gene therapy for dystrophic epidermolysis bullosa“
Janina Hahnloser, German Ministry of Health, Berlin, Germany
„SoHO and Implementation in Germany: Update and Perspective“
Dr. Bernd Schröder, Miltenyi Biotec B.V. & Co. KG, Bergisch-Gladbach, Germany
„Decentralized ATMP manufacturing: Opportunities and challenges“
Prof. Dr. Markus Mäurer, Champalimaud Foundation and Botton-Champalimaud Pancreatic Cancer Center, Lisboa Portugal / Johannes Gutenberg-Universität Mainz
„TIL-based cancer therapy and state of the art manufacturing of TILs“
Dr. Hans-Georg Eckert, Valicare GmbH – GMP-Dienstleister, Frankfurt/Main, Germany
GMP Manufacturing of Cell and Gene Therapy Drugs at Point of Care – Suitable Facility „Concepts and Scalable Solutions“
Stefan Gärtner, Labor LS SE & Co. KG, Bad Bocklet, Germany
„Solutions for rapid bioburden, sterility and endotoxin testing: Update and general requirements“
Dr. Thorsten Ulf Meyer, Granzer Regulatory Consulting & Services GmbH, Munich, Germany
„Comparison of interactions and submission pathways for ATMP in the US and EU: From pre-IND to marketing application“